Can a common supplement help dialysis patients?

NCT ID NCT07249229

Completed Disease control Sponsor: Darya Chamani Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether taking oral L-carnitine (a natural supplement) three times a week for three months could reduce inflammation and improve nutrition in 50 adults with advanced kidney failure on chronic hemodialysis. Participants were randomly assigned to receive either L-carnitine or a placebo. Researchers measured changes in blood markers of inflammation and nutrition to see if the supplement offers any benefit.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: L-carnitine
What this could lead to: If it works, this could point toward a simple supplement to help manage inflammation and nutrition in dialysis patients.
What could go wrong: This is a small, early-phase trial (50 people) testing only short-term effects. Results may not lead to a proven treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE (ESRD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease end stage renal failure Inflammation Malnutrition

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

END STAGE RENAL DISEASE (ESRD) HEMODIALYSIS

Contacts and locations

Locations

Bu Ali Hospital

Tehran, Tehran Province, 1711734365, Iran

More trials for these conditions

Other studies related to the condition(s) this trial covers.